Client 1ST Advisory Group LLC Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Client 1ST Advisory Group LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,588 shares of the medical research company’s stock after acquiring an additional 278 shares during the period. Client 1ST Advisory Group LLC’s holdings in IQVIA were worth $759,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jennison Associates LLC raised its stake in shares of IQVIA by 7.3% in the first quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after purchasing an additional 9,578 shares during the last quarter. Cadian Capital Management LP purchased a new stake in shares of IQVIA during the 4th quarter valued at about $70,108,000. Nomura Holdings Inc. purchased a new position in shares of IQVIA during the fourth quarter valued at approximately $857,000. PGGM Investments lifted its position in IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 4,326 shares during the period. Finally, Fiduciary Alliance LLC bought a new stake in IQVIA in the 1st quarter worth approximately $1,864,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $238.40 on Friday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $43.46 billion, a price-to-earnings ratio of 32.57, a price-to-earnings-growth ratio of 2.23 and a beta of 1.49. The firm has a 50 day moving average of $237.37 and a 200 day moving average of $234.53. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the previous year, the firm earned $2.22 EPS. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. UBS Group upped their target price on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Robert W. Baird lifted their target price on IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Barclays raised their target price on shares of IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Finally, Truist Financial upped their price target on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $266.67.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.